{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:23:45Z","timestamp":1794885825959,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Prostate cancer diagnosis heavily relies on histopathological evaluation, which is subject to variability. While immunohistochemical staining (IHC) assists in distinguishing benign from malignant tissue, it increases workload, costs, and leads to diagnostic delays. Artificial intelligence (AI) presents a promising solution to reduce reliance on IHC by accurately classifying atypical glands and borderline morphologies in hematoxylin and eosin (H&amp;E) stained tissue sections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<jats:bold>:<\/jats:bold>\n            <\/jats:title>\n            <jats:p>In this study, we evaluated an AI model\u2019s ability to minimize IHC use without compromising diagnostic accuracy. We retrospectively analyzed prostate core needle biopsies from routine diagnostics at three different pathology sites. These cohorts consisted exclusively of diagnostically challenging cases where pathologists had required IHC to finalize the diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We show that the AI model achieves high performance, with area under the curve values ranging from 0.951 to 0.993 for detecting cancer in routine H&amp;E-stained slides. When applying sensitivity-prioritized diagnostic thresholds, the model reduces the need for IHC staining by 44.4%, 42.0%, and 20.7% across the three cohorts, without a single false negative prediction. Among slides with a benign ground truth label, IHC use is reduced by up to 80.6%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This AI model shows promise for reducing unnecessary IHC use in difficult prostate biopsy cases while maintaining diagnostic safety. Its integration into clinical workflows could streamline decision-making in prostate pathology and alleviate resource burdens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s43856-025-01185-y","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T13:52:56Z","timestamp":1760536376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Artificial intelligence-assisted prostate cancer diagnosis for reduced use of immunohistochemistry"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9546-5443","authenticated-orcid":false,"given":"Anders","family":"Blilie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Mulliqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Szolnoky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5733-3178","authenticated-orcid":false,"given":"Sol Erika","family":"Boman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7893-7385","authenticated-orcid":false,"given":"Matteo","family":"Titus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine Martinez","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Asenjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Gambacorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Libretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Gudlaugsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7004-5533","authenticated-orcid":false,"given":"Svein R.","family":"Kjosavik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Egevad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel A. M.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5032-5266","authenticated-orcid":false,"given":"Martin","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9470-4783","authenticated-orcid":false,"given":"Kimmo","family":"Kartasalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"1185_CR1","doi-asserted-by":"crossref","unstructured":"Epstein, J. I., Allsbrook, W. C., Jr, Amin, M. B., Egevad, L. L. & ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 29, 1228\u20131242 (2005).","DOI":"10.1097\/01.pas.0000173646.99337.b1"},{"key":"1185_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0046-8177(92)90108-F","volume":"23","author":"DF Gleason","year":"1992","unstructured":"Gleason, D. F. Histologic grading of prostate cancer: a perspective. Hum. Pathol. 23, 273\u2013279 (1992).","journal-title":"Hum. Pathol."},{"key":"1185_CR3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1046\/j.1464-410X.2002.02669.x","volume":"89","author":"L Egevad","year":"2002","unstructured":"Egevad, L., Granfors, T., Karlberg, L., Bergh, A. & Stattin, P. Prognostic value of the Gleason score in prostate cancer. BJU Int. 89, 538\u2013542 (2002).","journal-title":"BJU Int."},{"key":"1185_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1080\/21681805.2016.1206619","volume":"50","author":"TA Ozkan","year":"2016","unstructured":"Ozkan, T. A. et al. Interobserver variability in Gleason histological grading of prostate cancer. Scand. J. Urol. 50, 420\u2013424 (2016).","journal-title":"Scand. J. Urol."},{"key":"1185_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1365-2559.2006.02393.x","volume":"48","author":"J Melia","year":"2006","unstructured":"Melia, J. et al. A UK-based investigation of inter- and intra-observer reproducibility of Gleason grading of prostatic biopsies. Histopathology 48, 644\u2013654 (2006).","journal-title":"Histopathology"},{"key":"1185_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1470-2045(19)30738-7","volume":"21","author":"P Str\u00f6m","year":"2020","unstructured":"Str\u00f6m, P. et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncol. 21, 222\u2013232 (2020).","journal-title":"Lancet Oncol."},{"key":"1185_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/his.12008","volume":"62","author":"L Egevad","year":"2013","unstructured":"Egevad, L. et al. Standardization of Gleason grading among 337 European pathologists: Gleason grading in Europe. Histopathology 62, 247\u2013256 (2013).","journal-title":"Histopathology"},{"key":"1185_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein, J. I. et al. The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 40, 244\u2013252 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"1185_CR9","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/PAS.0000000000000238","volume":"38","author":"JI Epstein","year":"2014","unstructured":"Epstein, J. I., Egevad, L., Humphrey, P. A. & Montironi, R. & Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am. J. Surg. Pathol. 38, e6\u2013e19 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"1185_CR10","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1038\/modpathol.2017.139","volume":"31","author":"C Magi-Galluzzi","year":"2018","unstructured":"Magi-Galluzzi, C. Prostate cancer: diagnostic criteria and role of immunohistochemistry. Mod. Pathol. 31, S12\u2013S21 (2018).","journal-title":"Mod. Pathol."},{"key":"1185_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2559.2005.02188.x","volume":"47","author":"M Varma","year":"2005","unstructured":"Varma, M. & Jasani, B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology 47, 1\u201316 (2005).","journal-title":"Histopathology"},{"key":"1185_CR12","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.5858\/2008-132-1388-BPIDIP","volume":"132","author":"GP Paner","year":"2008","unstructured":"Paner, G. P., Luthringer, D. J. & Amin, M. B. Best practice in diagnostic immunohistochemistry: Prostate carcinoma and its mimics in needle core biopsies. Arch. Pathol. Lab. Med. 132, 1388\u20131396 (2008).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1185_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.anndiagpath.2017.01.003","volume":"27","author":"S Al Diffalha","year":"2017","unstructured":"Al Diffalha, S. et al. Immunohistochemistry in the workup of prostate biopsies: Frequency, variation and appropriateness of use among pathologists practicing at an academic center. Ann. Diagn. Pathol. 27, 34\u201342 (2017).","journal-title":"Ann. Diagn. Pathol."},{"key":"1185_CR14","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.3390\/curroncol28030197","volume":"28","author":"P Mandel","year":"2021","unstructured":"Mandel, P. et al. Immunohistochemistry for prostate biopsy-impact on histological prostate cancer diagnoses and clinical decision making. Curr. Oncol. 28, 2123\u20132133 (2021).","journal-title":"Curr. Oncol."},{"key":"1185_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.5858\/arpa.2012-0145-OA","volume":"137","author":"K Watson","year":"2013","unstructured":"Watson, K., Wang, C., Yilmaz, A., Bismar, T. A. & Trpkov, K. Use of immunohistochemistry in routine workup of prostate needle biopsies: a tertiary academic institution experience. Arch. Pathol. Lab. Med. 137, 541\u2013545 (2013).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1185_CR16","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1038\/s41379-021-00826-6","volume":"34","author":"A Chatrian","year":"2021","unstructured":"Chatrian, A. et al. Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies. Mod. Pathol. 34, 1780\u20131794 (2021).","journal-title":"Mod. Pathol."},{"key":"1185_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/his.13760","volume":"74","author":"M Salto-Tellez","year":"2019","unstructured":"Salto-Tellez, M., Maxwell, P. & Hamilton, P. Artificial intelligence-the third revolution in pathology. Histopathology 74, 372\u2013376 (2019).","journal-title":"Histopathology"},{"key":"1185_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41591-021-01620-2","volume":"28","author":"W Bulten","year":"2022","unstructured":"Bulten, W. et al. Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nat. Med. 28, 154\u2013163 (2022).","journal-title":"Nat. Med."},{"key":"1185_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1470-2045(19)30739-9","volume":"21","author":"W Bulten","year":"2020","unstructured":"Bulten, W. et al. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. Lancet Oncol. 21, 233\u2013241 (2020).","journal-title":"Lancet Oncol."},{"key":"1185_CR20","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/s41591-019-0508-1","volume":"25","author":"G Campanella","year":"2019","unstructured":"Campanella, G. et al. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nat. Med. 25, 1301\u20131309 (2019).","journal-title":"Nat. Med."},{"key":"1185_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41746-022-00613-w","volume":"5","author":"A Esteva","year":"2022","unstructured":"Esteva, A. et al. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit. Med. 5, 71 (2022).","journal-title":"NPJ Digit. Med."},{"key":"1185_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s43856-021-00005-3","volume":"1","author":"E Wulczyn","year":"2021","unstructured":"Wulczyn, E. et al. Predicting prostate cancer specific-mortality with artificial intelligence-based Gleason grading. Commun. Med. 1, 10 (2021).","journal-title":"Commun. Med."},{"key":"1185_CR23","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1038\/s41591-024-03141-0","volume":"30","author":"E Vorontsov","year":"2024","unstructured":"Vorontsov, E. et al. A foundation model for clinical-grade computational pathology and rare cancers detection. Nat. Med. 30, 2924\u20132935 (2024).","journal-title":"Nat. Med."},{"key":"1185_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07441-w","author":"H Xu","year":"2024","unstructured":"Xu, H. et al. A whole-slide foundation model for digital pathology from real-world data. Nature https:\/\/doi.org\/10.1038\/s41586-024-07441-w (2024).","journal-title":"Nature"},{"key":"1185_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41591-024-02857-3","volume":"30","author":"RJ Chen","year":"2024","unstructured":"Chen, R. J. et al. Towards a general-purpose foundation model for computational pathology. Nat. Med. 30, 850\u2013862 (2024).","journal-title":"Nat. Med."},{"key":"1185_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41591-024-02856-4","volume":"30","author":"MY Lu","year":"2024","unstructured":"Lu, M. Y. et al. A visual-language foundation model for computational pathology. Nat. Med. 30, 863\u2013874 (2024).","journal-title":"Nat. Med."},{"key":"1185_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00428-023-03518-5","volume":"482","author":"C Eloy","year":"2023","unstructured":"Eloy, C. et al. Artificial intelligence-assisted cancer diagnosis improves the efficiency of pathologists in prostatic biopsies. Virchows Arch. 482, 595\u2013604 (2023).","journal-title":"Virchows Arch."},{"key":"1185_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37257-4","volume":"9","author":"W Bulten","year":"2019","unstructured":"Bulten, W. et al. Epithelium segmentation using deep learning in H&E-stained prostate specimens with immunohistochemistry as reference standard. Sci. Rep. 9, 864 (2019).","journal-title":"Sci. Rep."},{"key":"1185_CR29","unstructured":"Mulliqi, N. et al. Foundation models\u2014a panacea for artificial intelligence in pathology? arXiv https:\/\/arxiv.org\/abs\/2502.21264 (2025)."},{"key":"1185_CR30","doi-asserted-by":"publisher","first-page":"e097591","DOI":"10.1136\/bmjopen-2024-097591","volume":"15","author":"N Mulliqi","year":"2025","unstructured":"Mulliqi, N. et al. Development and retrospective validation of an artificial intelligence system for diagnostic assessment of prostate biopsies: study protocol. BMJ Open 15, e097591 (2025).","journal-title":"BMJ Open"},{"key":"1185_CR31","doi-asserted-by":"crossref","unstructured":"Xie, S., Girshick, R., Doll\u00e1r, P., Tu, Z. & He, K. Aggregated residual transformations for deep neural networks. arXiv https:\/\/arxiv.org\/abs\/1611.05431 (2016).","DOI":"10.1109\/CVPR.2017.634"},{"key":"1185_CR32","unstructured":"Tan, M. & Le, Q. V. EfficientNet: rethinking model scaling for convolutional neural networks. arXiv https:\/\/arxiv.org\/abs\/1905.11946 (2019)."},{"key":"1185_CR33","unstructured":"Loshchilov, I. & Hutter, F. Decoupled weight decay regularization. arXiv https:\/\/arxiv.org\/abs\/1711.05101 (2017)."},{"key":"1185_CR34","unstructured":"Zimmermann, E. et al. Virchow2: scaling self-supervised mixed magnification models in pathology. arXiv https:\/\/arxiv.org\/abs\/2408.00738 (2024)."},{"key":"1185_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"1185_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/modpathol.3800522","volume":"19","author":"L Egevad","year":"2006","unstructured":"Egevad, L., Allsbrook, W. C. & Epstein, J. I. Current practice of diagnosis and reporting of prostatic intraepithelial neoplasia and glandular atypia among genitourinary pathologists. Mod. Pathol. 19, 180\u2013185 (2006).","journal-title":"Mod. Pathol."},{"key":"1185_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/03008880510030923","volume":"39","author":"M Amin","year":"2005","unstructured":"Amin, M. et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand. J. Urol. Nephrol. Suppl. 39, 20\u201333 (2005).","journal-title":"Scand. J. Urol. Nephrol. Suppl."},{"key":"1185_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/bco2.60","volume":"2","author":"N Ranasinha","year":"2021","unstructured":"Ranasinha, N. et al. Ductal adenocarcinoma of the prostate: a systematic review and meta-analysis of incidence, presentation, prognosis, and management. BJUI Compass 2, 13\u201323 (2021).","journal-title":"BJUI Compass"},{"key":"1185_CR39","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"GJLH van Leenders","year":"2020","unstructured":"van Leenders, G. J. L. H. et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am. J. Surg. Pathol. 44, e87\u2013e99 (2020).","journal-title":"Am. J. Surg. Pathol."},{"key":"1185_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34945-8","volume":"13","author":"H Olsson","year":"2022","unstructured":"Olsson, H. et al. Estimating diagnostic uncertainty in artificial intelligence assisted pathology using conformal prediction. Nat. Commun. 13, 7761 (2022).","journal-title":"Nat. Commun."},{"key":"1185_CR41","doi-asserted-by":"publisher","first-page":"100715","DOI":"10.1016\/j.modpat.2025.100715","volume":"38","author":"X Ji","year":"2025","unstructured":"Ji, X. et al. Physical color calibration of digital pathology scanners for robust artificial intelligence-assisted cancer diagnosis. Mod. Pathol. 38, 100715 (2025).","journal-title":"Mod. Pathol."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01185-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01185-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01185-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T13:52:58Z","timestamp":1760536378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01185-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01185-y","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.M., L.E., K.K., and M.E. are shareholders of Clinsight AB. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"425"}}